Drug Reference for FDA Approved Parkinson's Disease Drugs @ Neurotransmitter.net


Advertisement



Generic Name:
amantadine hydrochloride

Trade Name:
Symmetrel ® [Endo]

IUPAC Name:
adamantan-1-amine hydrochloride

Dosage Forms/Routes:
Tablet/oral;
Syrup/oral;
Capsule/oral

Major Metabolite:
acetylamantadine

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
11/03/1980


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C10H18ClN

Molecular Mass:
187.709 g/mol

Indications:
Amantadine is indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.
Amantadine is also indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus.

Possible Mechanisms of Action:
At NMDA receptors, amantadine stabilizes closed channel states by accelerating channel closure; it also inhibits current flow through open NMDA receptor channels to a lesser degree (1). Amantadine's effects on NMDA receptors are greatest in the striatum (2). The drug may also decrease the rate of reactivation and act as a noncompetitive open channel blocker at nicotinic acetylcholine receptors such as those that contain the alpha7 subunit (3). In addition, amantadine is a weak agonist at sigma-1 receptors (4). Amantadine's antiviral utility results from its blockade of the influenza A virus M2 membrane protein (5). M2 proteins form proton-selective ion channels (6).

Chemical Class:
tricyclic amine

PubChem 2D Structure:

Generic Name:
apomorphine hydrochloride

Trade Name:
Apokyn ® [Mylan Bertek]

Common Chemical Name:
6ab-Aporphine-10,11-diol
hydrochloride hemihydrate

Dosage Forms/Routes:
Injectable/subcutaneous

Major Metabolite:
8-oxo-apomorphine-
semiquinone

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
04/20/2004


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C34H38Cl2N2O5

Molecular Mass:
625.581 g/mol

Indications:
Apomorphine is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson’s disease. Apomorphine has been studied as an adjunct to other medications (see CLINICAL PHARMACOLOGY: Clinical Trials in the prescribing information).

Possible Mechanisms of Action:
Apomorphine is an agonist at dopamine D1 (7), D2 (7), D3 (8), D4 (9), and D5 (10, 11) receptors. Apomorphine may also bind to alpha-2B-adrenoceptors and alpha-2C-adrenoceptors (10).

Chemical Class:
aporphine alkaloid of the dibenzoquinoline class

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link] 

Generic Name:
benztropine mesylate

Trade Name:
Cogentin ® [Merck]

IUPAC Name:
3-benzhydryloxy-8-methyl-8-
azabicyclo[3.2.1]octane;
methanesulfonic acid

Dosage Forms/Routes:
Tablet/oral;
Injectable/injection


Major Metabolites:
N-desmethylbenztropine;
benztropine N-oxide

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
03/05/1954


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C22H29NO4S

Molecular Mass:
403.536 g/mol

Indications:
Benztropine is indicated for use as an adjunct in the therapy of all forms of parkinsonism. The drug is also useful in the control of extrapyramidal disorders (except tardive dyskinesia) due to neuroleptic drugs (e.g., phenothiazines).

Possible Mechanisms of Action:
Benztropine is an antagonist at muscarinic acetylcholine M1, M2, M3, M4, and M5 receptors (12). Benztropine is also an antagonist at histamine H1 receptors (13, 14).

Chemical Class:
tropanol derivative

PubChem 2D Structure:

Generic Name:
biperiden hydrochloride

Trade Name:
Akineton ® [Abbott, Par]

IUPAC Name:
1-(5-bicyclo[2.2.1]hept-2-
enyl)-1-phenyl-3-(1-
piperidyl)propan-1-ol
hydrochloride

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
Unknown

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
09/08/1959


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C21H30ClNO

Molecular Mass:
347.922 g/mol

Indications:
Benztropine is indicated for use as an adjunct in the therapy of all forms of parkinsonism (idiopathic, postencephalitic, arteriosclerotic). The drug is also useful in the control of extrapyramidal disorders due to neuroleptic drugs (e.g. phenothiazines).

Possible Mechanisms of Action:
Biperiden is an antagonist at muscarinic acetylcholine M1 (15, 16), M2 (15, 16), M3 (15, 16), M4 (15, 16), and M5 receptors (16).

PubChem 2D Structure:

Generic Name:
bromocriptine mesylate

Trade Name:
Parlodel ® [Novartis]

Common Chemical Name:
ergotaman-3’,6’,18-trione,2-
bromo-12'-hydroxy-2'- (1-
methylethyl)-5'-(2-
methylpropyl)-,(5'a)
monomethanesulfonate (salt)

Dosage Forms/Routes:
Tablet/oral;
Capsule/oral

Major Metabolites:
2-bromolysergic acid;
2-bromoisolysergic acid

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
06/28/1978


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C33H44BrN5O8S

Molecular Mass:
750.701 g/mol

Possible Mechanisms of Action:
Bromocriptine is an agonist at dopamine D2 and D3 receptors (7, 10). Bromocriptine also binds to alpha-1A-adrenoceptors, alpha-1B-a drenoceptors, alpha-1D-adrenoceptors, alpha-2A-adrenoceptors, alpha-2B-adrenoceptors, and alpha-2C-adrenoceptors (10).
The drug may also bind to serotonin 5-HT1A (10), 5-HT1D (10), 5-HT2B (10), and 5-HT7 receptors (17). In addition, bromocriptine may accelerate the transport of glutamate mediated by hGluT-1 (29). The drug is also a potent free radical scavenger (30).

Indications:
Bromocriptine mesylate is in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing “end of dose failure” on levodopa therapy. Bromocriptine mesylate therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (“on-off” phenomenon). Continued efficacy of bromocriptine mesylate therapy during treatment of more than 2 years has not been established.

Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson’s disease with bromocriptine mesylate. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate therapy.

See the prescribing information for information about indications related to hyperprolactinemia-associated dysfunctions and acromegaly.

Chemical Class:
ergot derivative

PubChem 2D Structure:

Generic Name:
carbidopa

Trade Name:
Lodosyn ® [Bristol-Myers Squibb]

IUPAC Name:
3-(3,4-dihydroxyphenyl)-2-
hydrazinyl-2-methyl-propanoic
acid hydrate

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
a-methyl-3-methoxy-4-
hydroxyphenylpropionic acid;
a-methyl-3,4-
dihydroxyphenylpropionic acid

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
04/25/1977


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C10H16N2O5

Molecular Mass:
244.245 g/mol

Possible Mechanisms of Action:
Carbidopa is a peripheral aromatic L-amino acid decarboxylase (AADC) inhibitor (18). The drug, which does not cross the blood-brain barrier, is combined with levodopa to prevent its conversion to dopamine in the periphery (18).

Indications:
Lodosyn is indicated for use with Sinemet (carbidopa-levodopa) or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.

Lodosyn is for use with Sinemet (carbidopa-levodopa) in patients for whom the dosage of SINEMET (carbidopa-levodopa) provides less than adequate daily dosage (usually 70 mg daily) of carbidopa.

Lodosyn is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each entity.

Lodosyn is used with Sinemet (carbidopa-levodopa) or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from the addition of carbidopa.

Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B6), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as Sinemet (carbidopa-levodopa).

Although the administration of Lodosyn permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa.

Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa.

In considering whether to give Lodosyn with Sinemet (carbidopa-levodopa) or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial.

PubChem 2D Structure:

Generic Name:
carbidopa, entacapone, and levodopa

Trade Name:
Stalevo ® [Orion]

IUPAC Name:
3-(3,4-dihydroxyphenyl)-2-
hydrazinyl-2-methyl-propanoic
acid hydrate
; 2-cyano-3-(5-
dihydroxyamino-3,4-dioxo-1-
cyclohexa-1,5-dienyl)-N,N-
diethyl-prop-2-enamide;

2-amino-3-(3,4-dihydroxyphenyl)-
propanoic acid


Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
Carbidopa:
a-methyl-3-methoxy-4-
hydroxyphenylpropionic acid;
a-methyl-3,4-
dihydroxyphenylpropionic acid
Entacapone:
cis-entacapone;
entacapone glucuronide
Levodopa:
dopamine;
homovanillic acid

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]

Initial Approval:
06/11/2003


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Indications:
Stalevo (carbidopa, levodopa and entacapone) is indicated to treat patients with idiopathic Parkinson’s disease:

1. To substitute (with equivalent strength of each of the three components) for immediate-release carbidopa/levodopa and entacapone previously administered as individual products.

2. To replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose "wearing-off" (only for patients taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias, see DOSAGE AND ADMINISTRATION in the prescribing information).

Possible Mechanisms of Action:
Levodopa is the immediate precursor to dopamine.
Entacapone is a selective, reversible catechol-O-methyltransferase (COMT) inhibitor that increases the bioavailability of levodopa (19). Entacapone does not cross the blood-brain barrier (20). Carbidopa is a peripheral aromatic L-amino acid decarboxylase (AADC) inhibitor (18). Carbidopa, which also does not cross the blood-brain barrier, is combined with levodopa to prevent its conversion to dopamine in the periphery (18).

"3D" Structure of levodopa (Requires Chime):
[Link] 

Generic Name:
carbidopa and levodopa

Trade Name:
Sinemet ® [Bristol-Myers Squibb]

IUPAC Name:
3-(3,4-dihydroxyphenyl)-2-
hydrazinyl-2-methyl-propanoic
acid
; 2-amino-3-(3,4-
dihydroxyphenyl)-propanoic acid

Dosage Forms/Routes:
Tablet/oral;
Tablet (extended release)/oral

Major Metabolites:
Carbidopa:
a-methyl-3-methoxy-4-
hydroxyphenylpropionic acid;
a-methyl-3,4-
dihydroxyphenylpropionic acid

Levodopa:
dopamine;
homovanillic acid

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]

Initial Approval:
05/02/1975


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C19H25N3O8

Molecular Mass:
423.417 g/mol

Possible Mechanisms of Action:
Levodopa is the immediate precursor to dopamine. Carbidopa is a peripheral aromatic L-amino acid decarboxylase (AADC) inhibitor (18). Carbidopa, which does not cross the blood-brain barrier, is combined with levodopa to prevent its conversion to dopamine in the periphery (18).

Indications:
Sinemet is indicated in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), post-encephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Sinemet is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B6).

In some patients a somewhat smoother antiparkinsonian effect results from therapy with Sinemet than with levodopa. However, patients with markedly irregular ("on-off") responses to levodopa have not been shown to benefit from Sinemet.

Although the administration of carbidopa permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa.

Certain patients who responded poorly to levodopa have improved when Sinemet was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes.

In considering whether to give Sinemet to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing Sinemet with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial.

PubChem 2D Structure:

"3D" Structure of levodopa (Requires Chime):
[Link] 

Generic Name:
entacapone

Trade Name:
Comtan ® [Orion (marketed by Novartis)]

IUPAC Name:
2-cyano-3-(5-dihydroxyamino-
3,4-dioxo-1-cyclohexa-1,5-
dienyl)-N,N-diethyl-prop-2-
enamide

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
cis-entacapone;
entacapone glucuronide

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
10/19/1999


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C14H15N3O5

Molecular Mass:
305.286 g/mol

Indications:
Comtan is indicated as an adjunct to levodopa / carbidopa to treat patients with idiopathic Parkinson’s Disease who experience the signs and symptoms of end-of-dose “wearing-off” (see CLINICAL PHARMACOLOGY: Clinical Studies in the prescribing information).

Comtan’s effectiveness has not been systematically evaluated in patients with idiopathic Parkinson’s Disease who do not experience end-of-dose “wearing-off.”

Possible Mechanisms of Action:
Entacapone is a selective, reversible catechol-O-methyltransferase (COMT) inhibitor that increases the bioavailability of levodopa (19). Entacapone does not cross the blood-brain barrier (20).

Chemical Class:
nitrocatechol

PubChem 2D Structure:

Generic Name:
pergolide mesylate

Trade Name:
Permax ® [Eli Lilly]

Common Chemical Name:
8B-[(Methylthio)methyl]-6-
propylergoline
monomethanesulfonate

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
pergolide sulfone;
pergolide sulfoxide;
despropyl pergolide;
despropyl pergolide sulfoxide

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
12/30/1988


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C20H30N2O3S2

Molecular Mass:
410.596 g/mol

Indications:
Permax is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson’s disease.

Evidence to support the efficacy of pergolide mesylate as an antiparkinsonian adjunct was obtained in a multicenter study enrolling 376 patients with mild to moderate Parkinson’s disease who were intolerant to l-dopa/carbidopa as manifested by moderate to severe dyskinesia and/or on-off phenomena. On average, the patients evaluated had been on l-dopa/carbidopa for 3.9 years (range, 2 days to 16.8 years). The administration of pergolide mesylate permitted a 5% to 30% reduction in the daily dose of l/dopa. On average, these patients treated with pergolide mesylate maintained an equivalent or better clinical status than they exhibited at baseline.

Possible Mechanisms of Action:
Pergolide is an agonist at dopamine D2 and D3 receptors (10). It may also be a low potency agonist at dopamine D4 and D5 receptors (10). Pergolide may bind to alpha-2A-adrenoceptors, alpha-2B-adrenoceptors, alpha-2C-adrenoceptors (10). In addition, the drug may bind to serotonin 5-HT1A (10), 5-HT1D (10), 5-HT2B (10), 5-HT6 (21), and 5-HT7 recpetors (17, 21). Pergolide also inhibits voltage-gated potassium channels such as Kv1.5 (28).

Chemical Class:
ergot derivative

PubChem 2D Structure:

Generic Name:
pramipexole dihydrochloride

Trade Name:
Mirapex ® [Boehringer Ingelheim (marketed by Pfizer)]

IUPAC Name:
N'-propyl-4,5,6,7-
tetrahydrobenzothiazole-2,6-
diamine hydrate dihydrochloride

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
pramipexole is excreted primarily as unchanged drug

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
07/01/1997


Manufacturers:

[FDA Search]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C10H21Cl2N3OS

Molecular Mass:
302.265 g/mol

Indications:
Mirapex tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease.

The effectiveness of Mirapex was demonstrated in randomized, controlled trials in patients with early Parkinson’s disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa (see CLINICAL PHARMACOLOGY - CLINICAL STUDIES at RxList).

Possible Mechanisms of Action:
Pramipexole is an agonist at dopamine D2 and D3 receptors (22). It is more potent at D3 receptors (22).

Chemical Class:
tetrahydrobenzothiazole derivative

PubChem 2D Structure:

Generic Name:
procyclidine hydrochloride

Trade Name:
Kemadrin ® [Monarch]

IUPAC Name:
1-cyclohexyl-1-phenyl-3-
pyrrolidin-1-yl-propan-1-ol
hydrochloride

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
1-(cis-4-hydroxycyclohexyl)-1-
phenyl-3-(1-pyrrolidinyl)-1-
propanol;
1-(trans-4-hydroxycyclohexyl)-1-
phenyl-3-(1-pyrrolidinyl)-1-
propanol

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
07/27/1955


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

Empirical Formula:
C19H30ClNO

Molecular Mass:
323.9 g/mol

Indications:
Procyclidine is indicated in the treatment of parkinsonism including the postencephalitic, arteriosclerotic, and idiopathic types. Partial control of the parkinsonism symptoms is the usual therapeutic accomplishment. Procyclidine is usually more efficacious in the relief of rigidity than tremor; but tremor, fatigue, weakness, and sluggishness are frequently beneficially influenced. It can be substituted for all the previous medications in mild and moderate cases. For the control of more severe cases, other drugs may be added to procyclidine therapy as indications warrant.

Clinical reports indicate that procyclidine often successfully relieves the symptoms of extrapyramidal dysfunction (dystonia, dyskinesia, akathisia, and parkinsonism) which accompany the therapy of mental disorders with phenothiazine and rauwolfia compounds. In addition to minimizing the symptoms induced by tranquilizing drugs, the drug effectively controls sialorrhea resulting from neuroleptic medication. At the same time, freedom from the side effects induced by tranquilizer drugs, as provided by the administration of procyclidine, permits a more sustained treatment of the patient's mental disorder.

Possible Mechanisms of Action:
Procyclidine is an antagonist at M1, M2, M3, M4, and M5 muscarinic acetylcholine receptors (23). It is most potent at M1 receptors and least potent at M2 receptors (23).

Chemical Class:
piperidyl derivative

PubChem 2D Structure:

Generic Name:
ropinirole hydrochloride

Trade Name:
Requip ® [GlaxoSmithKline]

IUPAC Name:
4-(2-dipropylaminoethyl)-1,3-
dihydroindol-2-one hydrochloride

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
7-hydroxy ropinirole;
N-despropyl ropinirole

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
09/19/1997


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C16H25ClN2O

Molecular Mass:
296.835 g/mol

Indications:
Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.

The effectiveness of ropinirole was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY , Clinical Trials in the prescribing information).

Ropinirole is also indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Possible Mechanisms of Action:
Ropinirole is an agonist at dopamine D3 receptors (24). It is also a very low potency agonist at dopamine D2 receptors (24).

Chemical Class:
indolinone derivative

PubChem 2D Structure:

Generic Name:
selegiline hydrochloride

Trade Name:
Eldepryl ® [Somerset]

IUPAC Name:
N-methyl-1-phenyl-N-prop-2-
ynyl-propan-2-amine
hydrochloride

Dosage Forms/Routes:
Capsule/oral;
Tablet/oral

Major Metabolites:
N-desmethylselegiline;
L-methamphetamine;
L-amphetamine

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
05/15/1996


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C13H18ClN

Molecular Mass:
223.741 g/mol

Indications:
Selegiline is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy.

Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of 'off' time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state).

Possible Mechanisms of Action:
Selegiline is an irreversible inhibitor of monoamine oxidase B (MAO-B) (25). At higher than recommended doses, the drug inhibits MAO-A (see the prescribing information). Although selegiline weakly inhibits the reuptake of dopamine and norepinephrine, the drug's primary metabolite, l-methamphetamine, is a more potent inhibitor of dopamine and norepinephrine transporters (25).

Chemical Class:
levorotatory acetylenic derivative of phenethylamine

PubChem 2D Structure:

"3D" Structure (Requires Chime):
[Link]

Generic Name:
tolcapone

Trade Name:
Tasmar ® [Valeant]

IUPAC Name:
2-dihydroxyamino-4-(4-
methylbenzoyl)-cyclohexa-2,4-
diene-1,6-dione

Dosage Forms/Routes:
Tablet/oral

Major Metabolites:
3-O-beta, d-glucuronide conjugate of tolcapone;
3-O-methyltolcapone

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
01/29/1998


Manufacturers:

[FDA Search]

Prescribing Information:
[Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C14H11NO5

Molecular Mass:
273.241 g/mol

Indications:
Tolcapone is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson’s disease. Because of the risk of potentially fatal, acute fulminant liver failure, tolcapone should ordinarily be used in patients with Parkinson’s disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies. Because of the risk of liver injury and because tolcapone, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from t olcapone.

The effectiveness of tolcapone was demonstrated in randomized controlled trials in patients receiving concomitant levodopa therapy with carbidopa or another aromatic amino acid decarboxylase inhibitor who experienced end of dose wearing-off phenomena as well as in patients who did not experience such phenomena (see CLINICAL PHARMACOLOGY: Clinical Studies in the prescribing information).

Possible Mechanisms of Action:
Tolcapone is a selective, reversible catechol-O-methyltransferase (COMT) inhibitor that increases the bioavailability of levodopa (26). Unlike entacapone, tolcapone is able to cross the blood-brain barrier (27).

Chemical Class:
nitrocatechol

PubChem 2D Structure:

Generic Name:
trihexyphenidyl hydrochloride

IUPAC Name:
1-cyclohexyl-1-phenyl-3-(1-
piperidyl)propan-1-ol
hydrochloride

Dosage Forms/Routes:
Tablet/oral;
Elixir/oral

Major Metabolite:
hydroxylated metabolite of trihexyphenidyl

Database Search Links:
[PubMed]

[Search PubMed for
Randomized Controlled Trials
]

[
PubChem]
[PDSP Ki database]

Initial Approval:
05/13/1949


Manufacturers:

[FDA Search]

Prescribing Information:
[
Link]

RxList:
[
Link]

Epocrates:
[Link]

Empirical Formula:
C20H32ClNO

Molecular Mass:
337.927 g/mol

Indications:
Trihexyphenidyl is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones.

Possible Mechanisms of Action:
Trihexyphenidyl is an antagonist at M1, M2, M3, M4, and M5 muscarinic acetylcholine receptors (23). It is most potent at M1 receptors and least potent at M5 receptors (23).

Chemical Class:
piperidyl derivative

PubChem 2D Structure:

References:

1. Blanpied TA, Clarke RJ, Johnson JW.
Amantadine inhibits NMDA receptors by accelerating channel closure during channel block.
J Neurosci. 2005 Mar 30;25(13):3312-22. [Abstract]

2. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA.
Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine.
Eur J Neurosci. 1996 Mar;8(3):446-54. [Abstract]

3. Matsubayashi H, Swanson KL, Albuquerque EX.
Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons.
J Pharmacol Exp Ther. 1997 May;281(2):834-44. [Full Text]

4. Peeters M, Romieu P, Maurice T, Su TP, Maloteaux JM, Hermans E.
Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine.
Eur J Neurosci. 2004 Apr;19(8):2212-20. [Abstract]

5. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH.
Molecular basis of resistance of influenza A viruses to amantadine.
J Antimicrob Chemother. 1986 Oct;18 Suppl B:19-29. [Abstract]

6. Lear JD.
Proton conduction through the M2 protein of the influenza A virus; a quantitative, mechanistic analysis of experimental data.
FEBS Lett. 2003 Sep 18;552(1):17-22. [Abstract]

7. De Keyser J, De Backer JP, Wilczak N, Herroelen L.
Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum.
Prog Neuropsychopharmacol Biol Psychiatry. 1995 Nov;19(7):1147-54. [Abstract]

8. Sautel F, Griffon N, Levesque D, Pilon C, Schwartz JC, Sokoloff P.
A functional test identifies dopamine agonists selective for D3 versus D2 receptors.
Neuroreport. 1995 Jan 26;6(2):329-32. [Abstract]

9. Moreland RB, Terranova MA, Chang R, Uchic ME, Matulenko MA, Surber BW, Stewart AO, Brioni JD.
[3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
Eur J Pharmacol. 2004 Aug 23;497(2):147-54. [Abstract]

10. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A.
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. [Abstract]

11. Kudwa AE, Dominguez-Salazar E, Cabrera DM, Sibley DR, Rissman EF.
Dopamine D5 receptor modulates male and female sexual behavior in mice.
Psychopharmacology (Berl). 2005 Jul;180(2):206-14. [Abstract]

12. Bolden C, Cusack B, Richelson E.
Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells.
J Pharmacol Exp Ther. 1992 Feb;260(2):576-80. [Abstract]

13. McKearney JW.
Stimulant actions of histamine H1 antagonists on operant behavior in the squirrel monkey.
Psychopharmacology (Berl). 1982;77(2):156-8. [Abstract]

14. Kanba S, Richelson E.
Histamine H1 receptors in human brain labelled with [3H]doxepin.
Brain Res. 1984 Jun 18;304(1):1-7. [Abstract]

15. Lazareno S, Buckley NJ, Roberts FF.
Characterization of muscarinic M4 binding sites in rabbit lung, chicken heart, and NG108-15 cells.
Mol Pharmacol. 1990 Dec;38(6):805-15. [Abstract]

16. Eltze M.
Multiple mechanisms of action: the pharmacological profile of budipine.
J Neural Transm Suppl. 1999;56:83-105. [Abstract]

17. Shen Y, Monsma FJ Jr, Metcalf MA, Jose PA, Hamblin MW, Sibley DR.
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
J Biol Chem. 1993 Aug 25;268(24):18200-4. [Full Text]

18. Celesia GG, Wanamaker WM.
L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
Dis Nerv Syst. 1976 Mar;37(3):123-5. [Abstract]

19. Gottwald MD.
Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson's disease: review and current status.
Expert Opin Investig Drugs. 1999 Apr;8(4):453-62. [Abstract]

20. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A.
Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):186-9 [Abstract]

21. Boess FG, Martin IL.
Molecular biology of 5-HT receptors.
Neuropharmacology. 1994 Mar-Apr;33(3-4):275-317. [Abstract]

22. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM.
Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Eur J Pharmacol. 1995 Jun 23;290(1):29-36. [Abstract]

23. Bolden C, Cusack B, Richelson E.
Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells.
J Pharmacol Exp Ther. 1992 Feb;260(2):576-80. [Abstract]

24. Reavill C, Boyfield I, Coldwell M, Nelson P.
Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats.
J Pharm Pharmacol. 2000 Sep;52(9):1129-35. [Abstract]

25. Tekes K, Magyar K.
Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions.
Neurobiology (Bp). 2000;8(3-4):257-64. [Abstract]

26. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zurcher G, Da Prada M, van Brummelen P.
Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
Br J Clin Pharmacol. 1995 Sep;40(3):253-62. [Abstract]

27. Goetz CG.
Influence of COMT inhibition on levodopa pharmacology and therapy.
Neurology. 1998 May;50(5 Suppl 5):S26-30. [Abstract]

28. Hong Z, Smith AJ, Archer SL, Wu XC, Nelson DP, Peterson D, Johnson G, Weir EK.
Pergolide Is an Inhibitor of Voltage-Gated Potassium Channels, Including Kv1.5, and Causes Pulmonary Vasoconstriction.
Circulation. 2005 Aug 29; [Epub ahead of print] [Abstract]

29. Yamashita H, Kawakami H, Zhang YX, Tanaka K, Nakamura S.
Effect of amino acid ergot alkaloids on glutamate transport via human glutamate transporter hGluT-1.
J Neurol Sci. 1998 Feb 18;155(1):31-6. [Abstract]

30. Liu XH, Kato H, Chen T, Kato K, Itoyama Y.
Bromocriptine protects against delayed neuronal death of hippocampal neurons following cerebral ischemia in the gerbil.
J Neurol Sci. 1995 Mar;129(1):9-14. [Abstract]